Church Martin K, Church Diana S
Allergie-Centrum-Charité/ECARF, Charité-Universitätsmedizin Berlin, Germany.
Indian J Dermatol. 2013 May;58(3):219-24. doi: 10.4103/0019-5154.110832.
H1-antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago. They act as inverse agonists rather than antagonists of histamine H1-receptors which are members of the G-protein family. The older first generation H1-antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive. Their use should be discouraged. The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious. Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review. Of these levocetirizine and fexofenadine are the most potent in humans in vivo. However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection. Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.
H1抗组胺药是治疗荨麻疹的主要药物,70多年前从抗胆碱能药物发展而来。它们作为组胺H1受体的反向激动剂而非拮抗剂,组胺H1受体是G蛋白家族的成员。较老的第一代H1抗组胺药很容易穿透血脑屏障,导致镇静、嗜睡、疲劳以及注意力和记忆力受损,对儿童的学习和考试表现以及成人的工作和驾驶能力造成不利影响。应不鼓励使用它们。较新的第二代H1抗组胺药更安全,引起的镇静作用更少且更有效。本文综述重点介绍了三种广泛用于缓解荨麻疹症状的药物,即地氯雷他定、左西替利嗪和非索非那定。其中,左西替利嗪和非索非那定在人体体内作用最强。然而,左西替利嗪可能会使易感个体出现嗜睡,而非索非那定的作用持续时间相对较短,可能需要每日服用两次才能提供全面的日常保护。虽然地氯雷他定的效力较弱,但它具有很少引起嗜睡且作用持续时间长的优点。